专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11926574B2 Dimethoxyphenylalkylamine activators of serotonin receptors 有权
公开(公告)号：US11926574B2
公开(公告)日：2024-03-12
申请号：US17835764
申请日：2022-06-08
申请人： Entheogenix Biosciences, Inc.
发明人： Glenn Short , Robert B. Perni , Benjamin Robert Difrancesco , Tanweer A. Khan
IPC分类号： C07C225/16 , C07C381/10
CPC分类号： C07C225/16 , C07C381/10
摘要： Provided herein are compounds of Formula (I), or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and n are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or pharmaceutically acceptable salt thereof, and methods of using a compound of Formula (I) or pharmaceutically acceptable salt thereof, e.g., in the treatment of a mental health disease or disorder.

2. 发明授权

US10919841B2 Monoamine reuptake inhibitors 有权
公开(公告)号：US10919841B2
公开(公告)日：2021-02-16
申请号：US15388770
申请日：2016-12-22
申请人： Research Triangle Institute
发明人： Frank Ivy Carroll , Bruce Edward Blough , Philip Abraham
IPC分类号： C07C225/16 , C07C211/27 , C07C211/29 , C07C211/35 , C07C225/18
摘要： The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.

3. 发明申请

US20200290949A1 FORMAMIDE MONOMERS AND POLYMERS SYNTHESIZED THEREFROM 审中-公开
公开(公告)号：US20200290949A1
公开(公告)日：2020-09-17
申请号：US16815772
申请日：2020-03-11
申请人： Wisconsin Alumni Research Foundation
发明人： Padma Gopalan , Balamurugan Ayyakkalai , Ri Chen
IPC分类号： C07C225/16 , C07C225/14 , C08F12/26
摘要： Formamide group-containing monomers and polymers made by polymerizing the monomers are provided. Also provided are methods of polymerizing the monomers and methods of synthesizing functionalized polymers by pre- and/or post-polymerization functionalization. The monomers are non-toxic and can generate highly reactive isocyanate and isonitrile precursors in a one-pot synthesis that enables the incorporation of complex functionalities into the side-chain of the polymers that are synthesized from the monomers.

4. 发明申请

US20200223826A1 Glucose-6-Phosphate Dehydrogenase (G6PD)-Modulating Agents And Methods Of Treating G6PD Deficiency 审中-公开
公开(公告)号：US20200223826A1
公开(公告)日：2020-07-16
申请号：US16632863
申请日：2018-07-24
申请人： The Board of Trustees of the Leland Stanford Junior University
发明人： Sunhee Hwang , DARIA MOCHLY-ROSEN , CHE-HONG CHEN , Andrew Goodwin Raub
IPC分类号： C07D403/10 , C07D407/10 , C07D407/12 , C07D403/12 , C07C215/32 , C07C225/16 , C07D401/12 , C07D409/12 , C07C211/27 , C07C211/42 , C07D487/04 , C07D471/04 , C07D471/06
摘要： Aspects of the present disclosure include G6PD-modulating agents and methods for modulating a glucose-6-phosphate dehydrogenase (G6PD) in a sample using such agents. A G6PD-modulating agent can be dimeric and include two terminal carbocyclic or heterocyclic groups connected via a linker. In some instances, the agent includes a diamino-containing linker. In certain cases, the agent includes two amino substituents. Also provided are methods for treating a subject for a G6PD deficiency-associated condition, that include administering to a subject an effective amount of a G6PD-modulating agent to selectively activate a mutant G6PD and treat the subject. Kits and compositions for practicing the subject methods are also provided.

5. 发明授权

US10188615B2 Alkoxy compounds for disease treatment 有权
公开(公告)号：US10188615B2
公开(公告)日：2019-01-29
申请号：US15672031
申请日：2017-08-08
申请人： Acucela Inc.
发明人： Ian L. Scott , Vladimir A. Kuksa , Mark W. Orme , Thomas L. Little, Jr. , Anna Gall , Feng Hong
IPC分类号： C09B11/02 , A61K31/137 , A61K31/222 , A61K31/165 , C07C323/33 , C07C215/20 , C07D309/06 , C07D277/24 , C07C323/25 , C07C317/28 , C07C279/08 , C07C251/86 , C07C235/08 , C07C233/18 , C07C229/38 , C07C225/16 , C07C217/72 , C07C217/64 , C07C217/62 , C07C217/60 , C07C217/20 , C07C217/84 , C07C309/06
摘要： The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.

6. 发明授权

US10040752B2 Synthesis of levomethadone hydrochloride or dextromethadone hydrochloride and methods for use thereof 有权
公开(公告)号：US10040752B2
公开(公告)日：2018-08-07
申请号：US15245935
申请日：2016-08-24
申请人： Cody Laboratories, Inc.
发明人： Gnel Mkrtchyan , Qingwei Yao
IPC分类号： C07C221/00 , C07C225/16 , C07C213/00 , C07C227/18 , C07C253/30
摘要： Highly efficient methods for synthesis of levomethadone hydrochloride or dextromethadone hydrochloride are provided starting from D-alanine, or L-alanine, respectively, with retention of configuration. Methods for treating a subject are provided comprising administering a composition comprising an effective amount of levomethadone hydrochloride having not more than 10 ppm dextromethadone.

7. 发明授权

US09562001B2 Monoamine reuptake inhibitors 有权
标题翻译：单胺再摄取抑制剂
公开(公告)号：US09562001B2
公开(公告)日：2017-02-07
申请号：US13271419
申请日：2011-10-12
申请人： Frank Ivy Carroll , Bruce Edward Blough , Philip Abraham
发明人： Frank Ivy Carroll , Bruce Edward Blough , Philip Abraham
IPC分类号： A61K31/137 , C07C225/18 , A61P25/24 , A61P3/04 , A61P25/34 , A61P25/00 , A61P3/00 , A61P25/16 , A61P25/22 , A61P25/06 , A61P25/36 , A01N33/24 , C07C225/16 , C07C211/27 , C07C211/29 , C07C211/35
CPC分类号： C07C225/16 , C07C211/27 , C07C211/29 , C07C211/35 , C07C225/18 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14
摘要： The invention provides bupropion analog compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.
摘要翻译：本发明提供能够抑制一种或多种单胺再摄取的安非他酮类似物。化合物可以选择性地结合一种或多种单胺转运蛋白，包括用于多巴胺，去甲肾上腺素和5-羟色胺的单胺转运蛋白。这样的化合物可用于治疗对单胺再摄取的抑制作用有反应的病症，包括成瘾，抑郁和肥胖。

8. 发明授权

US09481680B2 Process for the preparation of key intermediates of omarigliptin 有权
标题翻译： omarigliptin的重要中间体的制备方法
公开(公告)号：US09481680B2
公开(公告)日：2016-11-01
申请号：US14900858
申请日：2015-01-19
申请人： F.I.S.—FABBRICA ITALIANA SINTETICI S.P.A.
发明人： Ottorino De Lucchi , Enrico Rosso , Simone Zaramella , Stefano Tartaggia
IPC分类号： C07C271/18 , C07C221/00 , C07C225/10 , C07C245/24 , C07D309/14 , C07D487/04 , C07C225/16 , C07C269/08
CPC分类号： C07D487/04 , C07C221/00 , C07C225/10 , C07C225/16 , C07C245/24 , C07C269/08 , C07D309/14 , C07C271/18
摘要： An improved process for the preparation of a key intermediate for the synthesis of the active ingredient Omarigliptin is provided. The key intermediate is a compound having the following formula (I) wherein R1 is propargyl or allyl group and P is an amine protecting group. The compound of formula (I) is prepared by converting a compound of formula (IV) by an amination reaction to a compound of formula (III), which is then protected to provide a compound of formula (II), which is then alkylated to provide the compound of formula (I).

9. 发明授权

US09266817B2 Catecholamine derivatives for obesity and neurological disorders 有权
标题翻译：儿茶酚胺衍生物用于肥胖和神经障碍
公开(公告)号：US09266817B2
公开(公告)日：2016-02-23
申请号：US14336911
申请日：2014-07-21
申请人： EMORY UNIVERSITY
发明人： Keqiang Ye
IPC分类号： A61K31/05 , A61K31/12 , A61K31/133 , A61K31/135 , C07C225/16 , C07C215/60 , C07C237/20 , A61K31/137
CPC分类号： C07C225/16 , A61K31/05 , A61K31/12 , A61K31/133 , A61K31/135 , A61K31/137 , C07C215/60 , C07C237/20
摘要： Novel compounds, compositions, and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of a compound containing a catecholamine backbone and pharmaceutically acceptable salts, prodrugs, and derivatives thereof. Specifically, methods, compositions, and compounds for the treatment of disorders including neurological disorders, neuropsychiatric disorders, and metabolic disorders are provided. For example, a first method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes administering to the subject a therapeutically effective amount of the described compounds. A further method of promoting neuroprotection in a subject also is provided, which includes administering to the subject a therapeutically effective amount of the described compounds.
摘要翻译：提供了与TrkB受体活化相关的新型化合物，组合物和方法。所述方法包括在体内或体外施用治疗有效量的含有儿茶酚胺骨架的化合物及其药学上可接受的盐，前药和衍生物。具体地，提供了用于治疗包括神经障碍，神经精神障碍和代谢紊乱的疾病的方法，组合物和化合物。例如，提供了治疗或降低受试者的抑郁，焦虑或肥胖的风险的第一种方法，其包括向受试者施用治疗有效量的所述化合物。还提供了在受试者中促进神经保护作用的另一种方法，其包括向受试者施用治疗有效量的所述化合物。

10. 发明授权

US09212160B2 Photoinitiators 有权
标题翻译：光引发剂
公开(公告)号：US09212160B2
公开(公告)日：2015-12-15
申请号：US14576237
申请日：2014-12-19
申请人： Coloplast A\S
发明人： Niels Joergen Madsen , Petr Sehnal , Christian B. Nielsen , David George Anderson
IPC分类号： C07D335/16 , C07D207/416 , C08F2/50 , C08G18/32 , C08G18/48 , C08G18/50 , C08G18/73 , C08G18/75 , C07C217/22 , C07C225/16 , C07C225/22 , C08J3/24 , C08J3/28 , C09D175/12 , C07C213/02 , C07C221/00 , C07C217/62
CPC分类号： C07D335/16 , C07C213/02 , C07C217/22 , C07C217/62 , C07C221/00 , C07C225/16 , C07C225/22 , C07D207/416 , C08F2/50 , C08G18/3275 , C08G18/4833 , C08G18/5024 , C08G18/5072 , C08G18/73 , C08G18/758 , C08J3/24 , C08J3/28 , C08J2375/00 , C09D175/12
摘要： The present invention provides novel photoinitiators for polyurethane formation, in which a photoinitiator moiety and a tertiary amine are incorporated into the photoinitiator structure, and thus the polyurethane polymer.
摘要翻译：本发明提供了用于聚氨酯形成的新型光引发剂，其中将光引发剂部分和叔胺引入到光引发剂结构中，从而聚氨酯聚合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式